Shanghai Bao Pharmaceuticals (SEHK:2659) Revenue Surges 7x While Losses Challenge Bullish Narratives

Shanghai Bao Pharmaceuticals (SEHK:2659) has reported its FY 2025 first half with revenue of C¥42.0 million and a basic EPS loss of C¥3.18, while trailing twelve month figures show revenue of C¥49.2 million against a net loss of C¥395.3 million and EPS of C¥1.36 in the red. Over the past few reporting halves, revenue has moved from C¥1.49 million in 2024 H1 to C¥4.67 million in 2024 H2 and then to C¥42.0 million in 2025 H1, as EPS stayed firmly negative across all periods. This sets up a picture of expanding top line alongside deeply loss-making margins that investors will want to weigh carefully.

See our full analysis for Shanghai Bao Pharmaceuticals.

With the headline numbers on the table, the next step is to set them against the prevailing narratives around growth potential, risks, and profitability to see which views hold up and which may need a rethink.

Curious how numbers become stories that shape markets? Explore Community Narratives

Revenue up 7x year on year, losses still heavy

• On a trailing twelve month view, revenue of C¥49.2 million compares with C¥6.16 million in 2024 H2, while net income stayed deeply negative at a C¥395.3 million loss.
• Supporters who focus on a strong top line story can point to revenue rising to C¥41.99 million in 2025 H1 from C¥1.49 million in 2024 H1, yet that bullish angle runs into the reality that losses also remained large, with net income loss widening from C¥167.3 million to C¥183.1 million over the same halves.
  • This pattern shows revenue multiple times higher than a year earlier, while trailing twelve month losses of C¥395.3 million are still far larger than any single period revenue figure.
  • For a bullish view to be fully supported, investors would usually look for some sign in the numbers that higher revenue is starting to make a visible dent in those losses, which is not evident here.

High P/B multiple against persistent losses

• The shares trade on a P/B of 16.2x, above the 14.2x peer average and well above the 4.5x Hong Kong biotech industry average, even though the company was unprofitable over the trailing twelve months.
• Critics who take a bearish stance often worry when a loss making business carries a richer book value multiple than peers, and the combination of a C¥395.3 million trailing twelve month net loss with a 16.2x P/B compared with 4.5x for the wider biotech group gives that bearish concern clear numerical backing.
  • The valuation gap versus both peers and the broader industry sits alongside no reported profit on a trailing basis, which is exactly the type of mismatch bears tend to flag.
  • Any bearish case tied to valuation risk will likely keep pointing back to this mix of higher than average P/B and ongoing losses when assessing downside scenarios.

Skeptical investors are watching this mix of rich P/B and continued losses closely, and you can see how that thinking stacks up against the detailed bear case in the 🐻 Shanghai Bao Pharmaceuticals Bear Case

Volatile share price on very large revenue shift

• Over the last 12 months, revenue growth was described as about 7x while the share price has been highly volatile over the past 3 months versus the Hong Kong market, with no earnings growth forecasts or DCF fair value estimates provided alongside the current C¥89.80 share price.
• What stands out against a bullish growth story is how a very large revenue change and ongoing losses sit next to that recent share price volatility, so investors weighing a growth angle will probably pay close attention to whether swings in the stock are being driven by the reported 7x revenue increase, the C¥395.3 million trailing twelve month loss, or a mix of both.
  • The scale of revenue change compared with the prior year highlights how sensitive the stock can be to growth headlines when the business is still reporting sizeable losses.
  • Recent volatility alongside these numbers means anyone leaning bullish or bearish is effectively reacting to the same data set, just putting different weight on rapid revenue growth versus the lack of reported profitability.

With both the sharp revenue jump and recent price swings in view, it helps to see how other investors connect these dots in their own narratives about the company, which you can do through the See what the community is saying about Shanghai Bao Pharmaceuticals.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Shanghai Bao Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With sentiment split between rapid revenue change, heavy losses and a rich P/B, it makes sense to review the numbers directly and decide quickly how you see the balance of risk and reward, starting with the 1 key reward and 1 important warning sign.

See What Else Is Out There

Shanghai Bao Pharmaceuticals combines heavy trailing twelve month losses, a rich 16.2x P/B and no reported profitability, which keeps valuation risk firmly in focus for investors.

If that mix of deep losses and a high book value multiple makes you uncomfortable, consider balancing your watchlist with 281 resilient stocks with low risk scores that prioritise more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com